Altimmune ALT shares are trading higher after the company announced interim data from its ALT-801 Phase 1 trial. Weight loss of 5.4% at 6 weeks was achieved, surpassing the pre-established target of 2%.
The company plans to file an additional IND and initiate an obesity program in 2021.
Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases.
At the time of publication, Altimmune shares were trading 29.2% higher at $18.27. The stock has a 52-week low of $6.88 and a 52-week high of $35.10.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
